Cite
In vitro and in vivo evidence discourages routine testing and reporting of piperacillin/tazobactam susceptibility of Elizabethkingia species.
MLA
Tan, Mei-Chen, et al. “In Vitro and in Vivo Evidence Discourages Routine Testing and Reporting of Piperacillin/Tazobactam Susceptibility of Elizabethkingia Species.” Journal of Antimicrobial Chemotherapy (JAC), vol. 79, no. 1, Jan. 2024, pp. 200–02. EBSCOhost, https://doi.org/10.1093/jac/dkad322.
APA
Tan, M.-C., Huang, Y.-C., Chen, P.-J., Huang, W.-C., Hsu, S.-Y., Wang, H.-Y., Liou, C.-H., Sun, J.-R., Lauderdale, T.-L. Y., & Kuo, S.-C. (2024). In vitro and in vivo evidence discourages routine testing and reporting of piperacillin/tazobactam susceptibility of Elizabethkingia species. Journal of Antimicrobial Chemotherapy (JAC), 79(1), 200–202. https://doi.org/10.1093/jac/dkad322
Chicago
Tan, Mei-Chen, Ying-Chi Huang, Pei-Jing Chen, Wei-Cheng Huang, Shu-Yuan Hsu, Hui-Ying Wang, Ci-Hong Liou, Jun-Ren Sun, Tsai-Ling Yang Lauderdale, and Shu-Chen Kuo. 2024. “In Vitro and in Vivo Evidence Discourages Routine Testing and Reporting of Piperacillin/Tazobactam Susceptibility of Elizabethkingia Species.” Journal of Antimicrobial Chemotherapy (JAC) 79 (1): 200–202. doi:10.1093/jac/dkad322.